AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Collaboration targets development of RC-529 adjuvant.
2003 SEP 10 - (NewsRx.com & NewsRx.net) -- Corixa Corp. (CRXA) and Apovia AG announced a research, development, and commercialization agreement for Corixa's synthetic adjuvant, RC-529.
The multiyear agreement grants Apovia commercial rights to RC-529 for use in an undisclosed therapeutic vaccine. Both companies will equally share research, development and commercialization costs, as well as any potential product revenue.
"RC-529 adjuvant is a synthetic adjuvant that has been shown to stimulate immune responses to multiple vaccine antigen formulations both in animal models and in man," said Steven Gillis, PhD, chairman and chief executive officer at Corixa. "We look forward to continuing the development of our adjuvant portfolio in a variety of clinical indications and, in particular, to working with Apovia on the development of therapeutic vaccines."
"Partnership opportunities such as this ...
- Corixa Announces First Approval of an Infectious Disease Vaccine Containing the...
- Press release article from: Business Wire September 8, 2003 700+ words
...prophylactic vaccine containing Corixa's synthetic RC-529(TM) adjuvant, for the...recombinant Hepatitis B antigen with Corixa's RC-529 adjuvant. An adjuvant is...vaccinated with SUPERVAX containing Corixa's RC-529 adjuvant after only two...
- Corixa Announces Adjuvant License and Supply Agreements with Aventis; Rights to...
- Press release article from: Business Wire March 30, 2004 700+ words
...agreements with Aventis for the use of Corixa's RC-529 adjuvant in the development...nonexclusive worldwide rights to Corixa's RC-529 adjuvant for use in multiple...placing annual orders for supply of Corixa's RC-529 adjuvant based on clinical...
- Corixa Initiates Phase III Pivotal Trial of RC-529 Synthetic Adjuvant for Use...
- Press release article from: Business Wire January 11, 2001 700+ words
...efficacy and safety of AgB plus Corixa's RC-529 to AgB alone in healthy adults...and chief executive officer of Corixa. "RC-529 is one of many interesting...responses, others, including Corixa's RC-552 cardioprotectant candidate...
- Corixa and Apovia AG Announce Collaboration Agreement for RC-529 Adjuvant.
- Press release article from: Business Wire August 14, 2003 700+ words
...commercialization agreement for Corixa's synthetic adjuvant, RC-529. The multiyear agreement...that the performance profile of Corixa's RC-529 adjuvant is ideally suited...and development at Apovia. Corixa's RC-529 Adjuvant RC-529 is the...
- Corixa Reports Positive Preliminary Results for Its Phase III Pivotal Trial of...
- Press release article from: Business Wire January 8, 2002 700+ words
...efficacy and safety of Corixa's RC-529 synthetic adjuvant...Hepatitis B vaccine plus Corixa's RC-529 adjuvant to vaccination...chief executive officer of Corixa. "We hope the data obtained...commercial development of RC-529 with Rhein Biotech...
- Corixa and Aventis sign RC-529 deal.(Aventis Pasteur )(Brief Article)
- Newspaper article from: Pharma Marketletter April 5, 2004 700+ words
The USA's Corixa Corp has reported the signing...for the use of the former's RC-529 adjuvant in the development...deal, Aventis Pasteur will pay Corixa upfront licence fees and performance...committed to placing yearly RC-529 supply orders based on...
- Corixa and Lorantis Announce Joint Collaboration to Develop Therapeutic...
- Press release article from: Business Wire March 3, 2005 700+ words
...B vaccine, containing Corixa's RC-529(TM) adjuvant...vaccine powered by our RC-529 adjuvant." "This partnership with Corixa should ensure that CV...infection or injury. RC-529 is Corixa's lead synthetic adjuvant...
- Corixa and CoPharma Collaborate to Develop and Commercialize Corixa's Novel...
- Press release article from: Business Wire January 17, 2001 700+ words
...commercialization agreement for Corixa's cardioprotectant, RC.552(TM). Under the terms...will develop and commercialize Corixa's RC.552 for the treatment and...cellular effects. For example, Corixa's RC-529(TM), now in Phase...
Source: HighBeam Research, Collaboration targets development of RC-529 adjuvant.